Share 'PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients'
PTC Therapeutics, Inc. today announced new data supporting the potential benefit of ataluren in preserving lung function in non-ambulatory people with nonsense mutation Duchenne. PPMD continues to urge the FDA to provide PTC with a full review and advisory committee meeting.
Read the announcement from PTC:
PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this